Regulatory Insider Filing: The Insider Charles Waite Unloaded 588024 shares of NanoString Technologies Inc (NASDAQ:NSTG)

November 24, 2016 - By Marie Mckinney

Regulatory Insider Filing: The Insider Charles Waite Unloaded 588024 shares of NanoString Technologies Inc (NASDAQ:NSTG)

Charles Waite Insider Sell

As exposed in a form that was submitted to the (SEC) on 22/11/2016, Charles Waite, director of Nanostring Technologies Inc and a well informed man, sold 588,024 shares of the company for around $12,495,510 U.S. Dollars at an average stock price per share of $21.3. He also unloaded 42,489 shares with value $873,574 USD in the last month. Currently, Mr. Charles, possess 1,707 shares, which accounts for 0.01% of the Company’s market cap. The insider’s activity definitely generated quite an interest in the stock community.

Insitutional Activity: The institutional sentiment increased to 2.83 in Q2 2016. Its up 0.31, from 2.52 in 2016Q1. The ratio improved, as 9 funds sold all NanoString Technologies Inc shares owned while 12 reduced positions. 15 funds bought stakes while 38 increased positions. They now own 16.55 million shares or 3.90% more from 15.93 million shares in 2016Q1.

Essex Invest Management Communication Ltd Liability Corp has 38,027 shares for 0.08% of their US portfolio. Creative Planning last reported 1,802 shares in the company. Rhumbline Advisers accumulated 14,636 shares or 0% of the stock. Price T Rowe Associates Md holds 136,670 shares or 0% of its portfolio. Acadian Asset Mgmt Limited Liability Company has 42,183 shares for 0% of their US portfolio. Tfs Capital Ltd Liability holds 0.06% or 26,384 shares in its portfolio. Commercial Bank Of America De holds 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG) for 3,610 shares. Cadian Cap Limited Partnership has 0.99% invested in the company for 1.43 million shares. Quantitative Systematic Strategies Limited Liability has 16,872 shares for 0.1% of their US portfolio. D E Shaw accumulated 59,841 shares or 0% of the stock. Northern Tru Corp last reported 182,960 shares in the company. Blackrock has 759 shares for 0% of their US portfolio. The California-based Endurant Capital Management Lp has invested 0.87% in NanoString Technologies Inc (NASDAQ:NSTG). Tower Rech Cap Limited Liability Co (Trc) has 167 shares for 0% of their US portfolio. Spark Ltd Com has 115,700 shares for 0.14% of their US portfolio.

Insider Transactions: Since August 12, 2016, the stock had 0 buys, and 11 selling transactions for $23.22 million net activity. $225,655 worth of NanoString Technologies Inc (NASDAQ:NSTG) was sold by JOHNSON JAMES A on Thursday, November 10. SAUNDERS BARNEY also sold $269,357 worth of NanoString Technologies Inc (NASDAQ:NSTG) on Thursday, November 10. $4.26 million worth of NanoString Technologies Inc (NASDAQ:NSTG) was sold by WAITE CHARLES P JR on Friday, August 12. GRAY R BRADLEY had sold 37,325 shares worth $839,279. Another trade for 3,961 shares valued at $65,357 was sold by BURNS WAYNE.

About 162,697 shares traded hands. NanoString Technologies Inc (NASDAQ:NSTG) has risen 38.40% since April 21, 2016 and is uptrending. It has outperformed by 33.07% the S&P500.

NanoString Technologies, Inc. develops and makes intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The company has a market cap of $476.31 million. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. It currently has negative earnings. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology.

According to Zacks Investment Research, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington.”

Analysts await NanoString Technologies Inc (NASDAQ:NSTG) to report earnings on March, 6. They expect $-0.45 EPS, down 2.27% or $0.01 from last year’s $-0.44 per share. After $-0.51 actual EPS reported by NanoString Technologies Inc for the previous quarter, Wall Street now forecasts -11.76% EPS growth.

Another recent and important NanoString Technologies Inc (NASDAQ:NSTG) news was published by Quotes.Wsj.com which published an article titled: “News NanoString Technologies Inc.NSTG” on June 26, 2013.

NSTG Company Profile

NanoString Technologies, Inc., incorporated on June 20, 2003, develops, makes and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Firm markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. The Firm has an installed base of over 350 systems, which its clients have used to publish more than 1,000 peer-reviewed papers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>